There is no established primary care solution for the rapidly increasing numbers of severely obese people with body mass index (BMI) >40 kg/m 2 .
INTRODUCTION
Severe obesity is increasing rapidly, with no established community-based solutions. A little higher than in the UK, the prevalence of body mass index (BMI) above 35 kg/m 2 in Scotland is now 6% in men and 11% in women, of whom 20% and 11% respectively (overall 14%) have diagnosed diabetes. 1, 2 By the age of 55-64 years, 5% of women and 3% of men exceed a BMI of 40 kg/ m 2 , risking multiple symptoms and major comorbidities. 3 Previous weight-management guidelines targeted BMI ≥30 kg/m 2 , with a 5-10% weight-loss and maintenance goal, derived from the Scottish Intercollegiate Guidelines Network (SIGN) 1996 target of 5-10 kg weight loss. 4 While a weight loss of 5-10 kg can prevent progression from impaired glucose tolerance to diabetes, and improves all metabolic markers, 5, 6 it does not reverse established diagnoses of diabetes, or its complications. The 2010 SIGN obesity guideline set a new target of ≥15% loss for those with BMI ≥35 kg/m 2 and with serious medical complications like type 2 diabetes. 7 A weight loss of ≥15 kg (close to 15% given a baseline weight of 104-106 kg) is needed to normalise both glucose and insulin, 8, 9 and virtually all patients who lost ≥15% or ≥15 kg in a controlled trial of bariatric surgery returned to normal glucose tolerance, 10 supporting extensive observational evidence. 11 Extrapolation of published audit data suggests that intentional weight loss of 15 kg might even normalise the reduced life expectancy of overweight patients with type 2 diabetes. 12 A target of sustained weight loss of more than 15 kg is essentially aspirational in routine clinical practice. 13 Only 1.7% maintained a weight loss of ≥15 kg in the original Counterweight Programme, which targeted 5-10% loss. With the addition of anti-obesity drugs, about 5-10%, and maybe 20% with liraglutide 3 mg/day, lose ≥15 kg. [14] [15] [16] [17] To lose 15 kg of adipose tissue, at 7000 kcal/kg, 18 demands a negative energy balance of about 100 000 kcal, assuming 2800 kcal/ day energy expenditure of obese patients. This is achievable in about 7 weeks with an 800 kcal/day diet. However, adherence is often incomplete, with little difference in 12-month weight change between lowenergy liquid diets (LELDs, ≥800-1200 kcal/ day) or very low-energy diets (VLEDs, 400-800 kcal/day). [19] [20] [21] With improved
Results
Of 91 patients (74 females) entering the programme (baseline: weight 131 kg, BMI 48 kg/ m 2 , age 46 years), 58/91(64%) completed the LELD stage, with a mean duration of 14.4 weeks (standard deviation [SD] = 6.0 weeks), and a mean weight loss of 16.9 kg (SD = 6.0 kg). Four patients commenced weight-loss maintenance omitting the food-reintroduction stage. Of the remaining 54, 37(68%) started and completed food reintroduction over a mean duration of 9.3 weeks (SD = 5.7 weeks), with a further mean weight loss of 2.1 kg (SD = 3.7 kg), before starting a long-term low-fat-diet weight-loss maintenance plan. A total of 44/91 (48%) received orlistat at some stage. At 12 months, weight was recorded for 68/91 (75%) patients, with a mean loss of 12.4 kg (SD = 11.4 kg). Of these, 30 (33% of all 91 patients starting the programme) had a documented maintained weight loss of ≥15 kg at 12 months, six (7%) had a 10-15 kg loss, and 11 (12%) had a 5-10 kg loss. The indicative cost of providing this entire programme for wider implementation would be £861 per patient entered, or £2611 per documented 15 kg loss achieved.
Conclusion
formulation and weight-regain-prevention programmes, safety concerns about VLEDs have declined, 22, 23 but they are seldom recommended in weight-management guidelines, because of the expected weight regain. However, meta-analysis showed a mean weight below baseline after 2 years, 15 and substantial numbers can maintain ≥15 kg loss 18-36 months after a VLED or LELD, using structured food-reintroduction programmes and anti-obesity drugs. 19, [24] [25] [26] The present feasibility study investigated the acceptability, adherence, and costs of a LELD intervention, aiming to achieve ≥15 kg weight loss at 12 months, among severely obese patients attending routine primary care.
METHOD
The feasibility study was conducted in practices already delivering Counterweight, 27 predominately in rural or small-town settings (16/25 providing 67% of study patients), nine of which were urban, in 7/13 Counterweight-trained health boards (Figure 1 ). Socioeconomic profiles of practice localities varied around the all-Scotland average: 96% of patients attended practices between the 20th and 80th percentiles of deprivation scores. 28 Six practice nurses and eight dietitians, competent in Counterweight Programme delivery, 29 attended 8 hours of training, delivered by Counterweight specialist dietitians and physicians with expertise in LELD, addressing the study protocol, programme delivery, and evaluation. Comprehensive educational resources for practitioners and patients were supplied, and Counterweight specialists provided on-the-job mentoring, and telephone/ email support, for programme-delivery staff. Expenses incurred for training were reimbursed, but the LELD programme was then delivered within routine practice, without additional incentives.
Participant numbers and representation
This feasibility study was not subject to power calculations. It aimed to recruit 60 patients, proposed by GPs, practice nurses, or local dietitians, over 6 months, anticipating 20-30% drop-outs, to leave 40 completing patients. Males and females, aged 20-60 years with BMI ≥40 kg/m 2 , were included if they were ready to undertake the programme. Exclusions were: pregnancy or lactation, diabetes and taking insulin or sulphonylureas, myocardial infarction within 6 months, cancers, chronic pancreatitis, alcohol dependence, psychiatric illness, and learning disability.
LELD stage (12 weeks or 20 kg weight loss, whichever was sooner) Following screening, to check inclusion criteria, readiness, and ability to commit to
How this fits in
It is a popular belief that liquid-formula diets are ineffective beyond an initial rapid weight loss, and that most people fail to maintain lower weight and will experience weight regain to above the baseline value. They are not routinely available or accepted in primary care. No effective approach other than bariatric surgery is offered to morbidly obese patients, and bariatric procedures have limited access in the current UK NHS. This study has shown that a low-energy liquid diet, with an effective 12-month weight-maintenance programme (including optional orlistat), is very acceptable to clinicians and to morbidly obese patients within routine primary care. A 12-month maintained weight loss of ≥15 kg (enough to reverse type 2 diabetes) was achieved by 31 of the 91 severely obese patients who entered the study, at an anticipated cost of £861 per patient if widely implemented.
British the 12-month LELD programme, patients were asked to follow either a 'home-made' milk-and fruit-juice-based diet (811 kcal/ day, 64 g protein, 132 g carbohydrate, 6 g fat) with a multivitamin/mineral supplement (Forceval ® [Alliance]), 30 or a micronutrientreplete commercial LELD (832 kcal/ day, 87 g protein, 120 g carbohydrate, 12 g fat) (Cambridge Weight Plan, UK). 'Mixing and matching' these diets was permitted, with optional LELD step-down from 1200 kcal/day to 810/832 kcal/day over 2 weeks, to optimise compliance. After 1 week, and fortnightly thereafter, a structured programme of topics was addressed, including weight-loss targets and expectations, relapse prevention, selfmonitoring, and social support, with written support materials, including detecting and managing problems. A fibre supplement (Fybogel ® [ispaghula husk, Reckitt Benckiser]) was prescribed as required, and advice to drink 2.25 l/day plus LELD soups/ shakes. Telephone support was offered.
Food reintroduction (6-8 weeks)
Initially, one 360-400 kcal meal, based on the 'eatwell plate', 31 plus two fruit servings/ day was introduced, the LELD was reduced, and orlistat offered (120 mg/meal). Allowing some individual flexibility, further meals were introduced fortnightly until LELD was replaced with three meals per day. Patients attended fortnightly, receiving printed support materials on weight-loss maintenance, nutrition, physical activity, goal setting, energy requirements, portion control, and orlistat, with telephone support if necessary.
Weight-loss maintenance (until 12 months)
Patients progressed gradually from their final food-reintroduction prescription (1400 kcal/day) to an individual 'prescribed eating plan', based on food portions containing 30% energy from fat, with a 500-600 kcal/day deficit below the requirement predicted from age, weight, and sex, 32 and an upper limit of 2500 kcal/day. 33 Thirty minutes per day of moderate physical activity was encouraged, 34 with sustainable individually-tailored goal setting to increase activity. 33 Patients attended monthly to consolidate strategies introduced during the LELD and food reintroduction, with early discussions on relapse prevention, goal setting, portion control, and physical activity. 
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RESULTS
Overall, at 12 months ±90 days, the mean weight loss was 12.4 kg (standard deviation [SD] = 11.4 kg; 9.1% loss, SD = 8.2%; n = 68). Thirty patients (33% of 91 entering the programme, 44% of those with 12-month weights) recorded a documented weight loss of ≥15 kg at 12 months, six lost 10-15 kg, 11 lost 5-10 kg, and 21 (31% of those with a 12-month weight) failed to reduce their weight by more than 5 kg. Weight loss of ≥15% was documented for 17 (19% of those entering, 25% of those with a 12-month weight). There were 29/58 who achieved ≥15 kg loss at 12 months within a measurement window of ±60 days and 27/45 within a window of ±30-days. Figure 2 ). At baseline, 82 patients chose the commercial LELD, two chose the homemade LELD, and six chose to use both (one not recorded). All patients used the commercial product at some point, 81 solely.
LELD stage
To optimise patient retention, some protocol variations were accepted, and their reasons contributed to learning about the feasibility. Three patients stopped the LELD at 8.2 weeks (SD = 3.5 weeks), starting food reintroduction before 12 weeks without losing 20 kg, with a mean weight loss of 16.5 kg (SD = 2.2 kg; 11.5% change, SD = 2.7%). Eleven lost ≥20 kg with the LELD and started food reintroduction before 12 weeks, according to protocol, with a weight loss of 22.7 kg (SD = 3.3 kg; 15.7% change, SD = 2.3%) over 9.1 weeks (SD = 2.3 weeks). Thirty-six continued the LELD beyond 12 weeks before food reintroduction, with a weight loss of 15.6 kg (SD = 5.7 kg; 12.2% change, SD = 4.8%) over 15.1 weeks (SD = 2.3 weeks). Four remained on the LELD beyond 12 weeks, commencing weight-loss maintenance directly (omitting food reintroduction), with weight loss of 11.3 kg (SD = 7.8 kg; 8.4% change, SD = 5.2%), after 29.6 weeks (SD = 11.6 weeks). Thirty-three patients withdrew from the study during the LELD, after 6.8 weeks (SD = 5.4 weeks), with a weight loss of 6.2 kg (SD = 6.6 kg; 5.1% change, SD = 5.2%).
The mean weight change was 16.9 kg (SD = 6.0 kg; 12.6% change, SD = 4.5%; n = 58), after 14.4 weeks (SD = 6.0 weeks) on the LELD. Forty-two (46% of enrolled patients, 69% of completers) lost ≥15 kg during the LELD, and 19 lost ≥15% (21% of enrolled patients, 33% of completers).
Food-reintroduction stage
Of 54 patients entering this stage, three returned to the LELD and three dropped out. The mean weight change during food reintroduction was -2.1 kg (SD = 3.7 kg), over 9.3 weeks (SD = 5.7 weeks). The mean difference from baseline was -19.1 kg (SD = 7.5 kg; -14.6%, SD = 5.1%; n = 48). By the end of food reintroduction, 37 patients had lost ≥15 kg (41% of all enrolled patients, 77% of patients who completed food reintroduction), and 26 had lost ≥15% (29% of all patients, 54% of food-reintroduction completers).
Weight-loss maintenance stage
Fifty-two patients commenced maintenance (48 after food reintroduction, four direct from the LELD) (Figure 3 ): 17 (33%) reverted to LELD and/or food reintroduction for short periods (Figure 4) .
Most patients (49, 94%) commencing weight-loss maintenance provided 12-month weights. The mean weight change from baseline to 12 months was -14.7 kg (SD = 10.8 kg, representing a regain of 3.6 kg (SD = 6.7 kg; 3.2% gain, SD = 5.9%) over 29 weeks (SD = 9 weeks) during weight-loss maintenance. A total weight loss of ≥15 kg was recorded for 27 patients (52% of patients who entered weight-loss maintenance, 55% of those who also provided 12-month weights). A weight loss of ≥15% was recorded for 15 (29% of those who entered weight-loss maintenance, 31% of those who also provided 12-month weights).
Twelve-month weights were also obtained for 19 (49%) of 39 patients who had withdrawn before weight-loss maintenance. They had lost 6.7 kg (SD = 11.1 kg; 4.6%, SD = 6.9%) from baseline, which was 0.5 kg (SD = 11.6 kg; 0.4%, SD = 6.9%) below their last recorded weight, over 39 weeks (SD = 10 weeks). Three of these 39 'dropouts' had lost ≥15 kg, and two had lost ≥15% (Figure 4 ).
Orlistat use
Only 29% (16/54) of patients accepted orlistat at the start of food reintroduction, but it was prescribed at some point to 44/91 patients (82% of those who entered weight-loss maintenance) for 26 weeks (SD = 15 weeks). The mean weight change at 12 months among those who had used orlistat at some point was -15.5 kg (SD = 11.1 kg; 11.3%, SD = 8.3%; n = 38), compared to -13.8 kg (SD = 8.4 kg; 11.0%, SD = 6.9%; n = 8) for those who did not. For patients receiving orlistat at 12 months (n = 18), the weight change was -20.1 kg (SD = 8.0 kg; -14.9%, SD = 6.0%), compared to -14.1 kg (SD = 11.4 kg; -10.5%, SD = 8.2%) for those not taking orlistat (n = 22). 17/38 (45%) of those attending practice nurses, and 16/53 (30%) of those attending dietitians (P = 0.15). Weight losses at LELD completion were similar (nurses 16.5 kg, SD = 6.2 kg; dietitians 17.1 kg, SD = 5.9 kg, P = 0.72). Weight losses at 12 months achieved by nurses and dietitians were also similar (10.5 kg, SD = 7.9 kg, versus 13.7 kg, SD = 13.1 kg; P = 0.25).
Practice nurses and dietitians for programme delivery

Delivery and acceptability of the LELD programme
The convenience sample for formal qualitative study was potentially biased towards patients who were more favourable towards the programme, and were protocol adherent (Appendix 1). However, there were 33% of withdrawals during the LELD, compared to 37% in unsampled patients. The qualitative analyses indicated that participants were 'very satisfied' with the rate and degree of weight loss with the LELD. Some experienced adverse physical effects such as constipation and dizziness, mostly transient, and participants appeared more concerned with social and occupational consequences. A common concern, for example, was over occasions such as family mealtimes and being confronted with food. For others, family members or friends felt uncomfortable eating around a person on the LELD. A key aspect of the programme is re-education of participants' eating habits to prevent weight regain after programme completion. Those interviewed reported increased awareness of the importance of balancing energy intake and expenditure, and described their strategies to monitor their energy intake over the day. They were not entirely confident that weight gain could be avoided after the LELD, although weightloss maintenance for 12 months was better than anticipated from other studies. 37 The practitioners interviewed were satisfied with the programme delivery, training, and support.
The cost of programme delivery Table 3 shows an estimate of the cost, per patient entered, that would be incurred for delivery of the programme within routine NHS primary care, based on observed times and resource use in this feasibility study. The total costing for the 12-month programme, assuming delivery of the programme solely by practice nurses, was £861 per patient entered, or £2611 per documented ≥15 kg 12-month-maintained loss, with 64% of the total cost incurred during the LELD (Appendix 2).
For £1million, this programme could treat 1161 patients, to result in 12 months' maintained weight losses of ≥15 kg for 383 patients, ≥10 kg loss for 459 patients, and ≥5 kg loss for 600 patients. For comparison, the cost of laparoscopic gastric banding surgery, including appropriate preoperative assessment, 12-months' postsurgical follow-up, and band adjustments and provision to manage those who develop post-operative complications, was estimated at £4988 using 2005 prices. 38 A more recent figure of £8349 was estimated by NHS Grampian. Assuming a figure of £7500, for a cost of £1 million, 133 patients could be treated with laparoscopic banding, and about 110 patients would lose ≥15 kg.
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DISCUSSION
Summary
The results of the present study contrast with some recent UK publications that have documented the weight losses currently achieved by obese patients in routine community settings. The LightenUp trial demonstrated that the level of weight loss observed in programmes such as those listed above is likely to be highly cost effective. 41 However, they do not provide the effect size required for patients with severe and complex obesity, whose sheer numbers demand a community-based solution.
Strengths and limitations
Recruitment methods may have varied between practices, to bias selection, either towards more intractable, or more compliant, patients. The present study is not a randomised controlled trial. It is difficult to recruit (particularly to a control group) and conduct such a study when a long-term outcome is desired, visible, and advertised elsewhere. A randomised controlled trial is scarcely needed to demonstrate efficacy, with results unlikely to have occurred by chance.
Comparison with existing literature At present, VLEDs or LELDs are seldom offered within the NHS, with scepticism over their effectiveness, and non-evidence-based fears of serious hazards. 23, 24 Delivering composite long-term, multi-component programmes is a relatively new demand for primary care: although staff received only very limited standard training, the practices in this study may not be representative in terms of commitment or skill in weight management. The programme examined in the present paper, combining a LELD with Counterweight weight-maintenance methods, aimed to achieve and maintain for 12 months a challenging ≥15 kg weight loss for severely obese patients, in a realistic routine care setting. Such results have been achieved in research clinics: either 450 kcal/day VLED or 810 kcal/day LELD for 9-16 weeks produced similar results, with a 2-week structured foodreintroduction and 12-month group-therapy weight-maintenance programme resulting in 12.1 kg weight loss (10.6%) (n = 63). 42 A multicentre German study with 800 kcal/ day LELD, and stepwise food reintroduction, reported 35% of entering patients maintained ≥15% 12-month weight loss. 43 A meta-analysis of VLEDs indicated that even without a long-term weight-maintenance programme, weights remained on average 3-6 kg below baseline at 12-24 months. 15 Combining a VLED with anti-obesity medication generates mean weight losses of near 15 kg maintained 12-24 months. 25 Implications for practice and research The present study helps inform future community-based studies around a full package of LELD, food reintroduction and long-term weight-loss maintenance. Alternatives include nutritionally complete commercial products, or cheaper 'homemade' liquid diets with vitamin/mineral supplements. 30 The present study was not designed to compare approaches, but establishes that both can valuably be delivered in a routine primary care setting. 44 Patients were initially reluctant to accept orlistat, but almost half agreed when faced with the realities of weight maintenance. The study results support published data for the efficacy of orlistat after VLED. 24 Practical issues around supply and storage of the LELD were not limiting. Lack of incentives in general practice for weight management may limit implementation. The high commitment shown for the present LELD programme appeared to arise from the magnitude of weight loss achieved for patients with long-standing severe obesity, for whom previous treatments had been ineffective. During study appointments, nurses reported having also dealt with other clinical matters for which the patients would otherwise have had to make extra appointments, and practitioners indicated that many of these patients would have occupied a similar amount of staff time for other reasons if they had not been engaged on the present programme. Thus the indicative cost of the programme, £861 per patient entered or £2611 per patient losing ≥15 kg, may be overestimated. These figures are highly relevant to service planners. Although major weight loss (for example, >30 kg) would be more frequent with bariatric surgery, many more patients with severe and complicated obesity would achieve the ≥15 kg loss, potentially sufficient to reverse type 2 diabetes, 10 if the same resource were spent on this LELD programme. This estimate assumes that practice nurses would deliver the programme in routine practice, as their results were little different from those of dietitians. The possibility of a difference cannot be excluded. More complicated and demanding patients may require more specialist individual contact. On the other hand, dietitians would be unable to deal with other intercurrent health problems during weight management.
Questions remain about weight-loss maintenance beyond 12 months: 23% of patients failed to engage, even to lose ≥5 kg at 12 months, a consistently frustrating finding in obesity trials. Few failed to lose any weight, indicating total failure to engage: full adherence to the LELD protocol, would have incurred a weight loss of ≥20 kg over 12 weeks.
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